Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody

Prostate-specific membrane antigen (PSMA) is expressed at high levels on malignant prostate cells and is likely an important therapeutic target for the treatment of prostate carcinoma. Current immunotherapy approaches to target PSMA include peptide, cell, vector or DNA-based vaccines as well as pass...

Descripción completa

Detalles Bibliográficos
Autores principales: Muthumani, Kar, Marnin, Liron, Kudchodkar, Sagar B., Perales-Puchalt, Alfredo, Choi, Hyeree, Agarwal, Sangya, Scott, Veronica L., Reuschel, Emma L., Zaidi, Faraz I., Duperret, Elizabeth K., Wise, Megan C., Kraynyak, Kimberly A., Ugen, Kenneth. E., Sardesai, Niranjan Y., Joseph Kim, J., Weiner, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676807/
https://www.ncbi.nlm.nih.gov/pubmed/28819703
http://dx.doi.org/10.1007/s00262-017-2042-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676807/
https://www.ncbi.nlm.nih.gov/pubmed/28819703
http://dx.doi.org/10.1007/s00262-017-2042-7

Ejemplares similares